CoChat

A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2

Open access
Nakai, Yousuke, Isayama, Hiroyuki, Ijichi, Hideaki, Sasaki, Takashi, Takahara, Naminatsu, Ito, Yukiko, Matsubara, Saburo, Uchino, Rie, Yagioka, Hiroshi, Arizumi, Toshihiko, Hamada, Tsuyoshi, Miyabayashi, Koji, Mizuno, Suguru, Yamamoto, Keisuke, Kogure, Hirofumi, Yamamoto, Natsuyo, Hirano, Kenji, Sasahira, Naoki, Tateishi, Keisuke, Tada, Minoru, Koike, Kazuhiko · 2013 · Investigational New Drugs
Cited by 51

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

SummaryBackground Our retrospective study and phase I trial of gemcitabine and candesartan combination therapy suggested the inhibition of renin-angiotensin system potentially has a role in the treatment of advanced pancreatic cancer. The aim of this multicenter phase II trial was to assess the efficacy and toxicity of gemcitabine and candesartan combination therapy for advanced pancreatic cancer. Methods Chemotherapy-naive patients with histologically or cytologically proven advanced pancreatic cancer were enrolled. Gemcitabine was administered at a dose of 1,000 mg/m2 over 30 min on days 1, 8, and 15 and oral candesartan at a dose of 16 mg in normotensive patients, and 8 mg initially in hypertensive patients, with dose escalation to 16 mg allowed, from days 1 to 28, repeated every 4 weeks. Results A total of 35 patients with advanced pancreatic cancer were enrolled. Overall response rate and disease control rate were 11.4 % and 62.9 %. The median PFS and OS were 4.3 and 9.1 months with 1-year survival rate of 34.2 %. The median PFS was significantly longer in patients receiving 16 mg compared with 8 mg of candesartan (4.6 vs. 3.5 months, p = 0.031). Major severe toxicities were neutropenia (23 %), leukopenia (17 %) and thrombocytopenia (11 %). Grade 2 hypotension was observed in 3 patients (9 %) and candesartan was discontinued in 2 patients due to hypotension. Conclusions In this multicenter phase 2 trial, gemcitabine and candesartan combination therapy was tolerable but failed to demonstrate activity against advanced pancreatic cancer. (UMIN CTR: UMIN000005580)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10637-013-9972-5

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 51

Metadata

Authors
Nakai, Y., Isayama, H., Ijichi, H., Sasaki, T., Takahara, N., Ito, Y., Matsubara, S., Uchino, R., Yagioka, H., Arizumi, T., Hamada, T., Miyabayashi, K., Mizuno, S., Yamamoto, K., Kogure, H., Yamamoto, N., Hirano, K., Sasahira, N., Tateishi, K., Tada, M., & Koike, K.
Venue
Investigational New Drugs
Published
2013-10
Volume
31
Issue
5
Pages
1294-1299
ISSN
  • 0167-6997 (ISSN-L)
  • 1573-0646
OpenAlex
W2071805383
Cited by
51
References
3
FWCI
2.53
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. https://app.cochat.ai/papers/10.1007/s10637-013-9972-5
The paper
Nakai, Y., Isayama, H., Ijichi, H., Sasaki, T., Takahara, N., Ito, Y., Matsubara, S., Uchino, R., Yagioka, H., Arizumi, T., Hamada, T., Miyabayashi, K., Mizuno, S., Yamamoto, K., Kogure, H., Yamamoto, N., Hirano, K., Sasahira, N., Tateishi, K., . . . Koike, K. (2013). A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. Investigational New Drugs. https://doi.org/10.1007/s10637-013-9972-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.